Wells Fargo maintains Buy on Voyager Therapeutics stock at USD 10.00

Published on 10/07/2026 at 08:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wells Fargo's October 2, 2026 note sets a USD 10.00 target. Voyager Therapeutics stock costs EUR 2.19 versus EUR 2.18, plus 0.46 percent.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (ISIN US92915B1061) was trading at EUR 2.19 at Lang & Schwarz on October 7, 2026 at 7:57 a.m. CEST, plus 0.46 percent versus the prior close of EUR 2.18. The latest analyst action is a maintained Buy rating and USD 10.00 price target from Wells Fargo, according to Markets Insider on October 5, 2026, citing an October 2 report.

Wells Fargo keeps a USD 10.00 target

Wells Fargo's target stands well above the German-market euro quote, but the currencies represent different trading venues and are not directly interchangeable. The analyst action gives VYGR a concrete valuation reference while the stock remains in the pre-market phase for Xetra investors.

Markets Insider reported that Voyager's second-quarter 2026 revenue was USD 3.17 million, down from USD 5.20 million in the year-earlier quarter. The company also posted a GAAP net loss of USD 24.47 million, compared with a GAAP net loss of USD 33.38 million a year earlier.

Revenue and loss remain key measures

The second-quarter comparison shows two different signals: revenue declined, while the GAAP net loss narrowed by USD 8.91 million. For a clinical-stage biotechnology company, that combination places the emphasis on pipeline progress and financing capacity rather than sales growth alone.

Voyager describes its business as a biotechnology platform focused on neurological diseases, including Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and Friedreich ataxia, according to its investor-relations profile. Its TRACER AAV capsid platform and partnerships with Alexion, AstraZeneca Rare Disease, Novartis and Neurocrine shape the longer-term development case.

VYGR stays near its yearly low

The primary listing is Nasdaq in USD. The finance quote showed a market capitalization of USD 148.6 million and a 52-week range of USD 2.39 to USD 5.55 as of October 6, 2026, placing the latest US-market reference near the lower end of that range.

At Lang & Schwarz, Voyager Therapeutics was trading at EUR 2.19 on October 7, 2026 at 7:57 a.m. CEST, plus 0.46 percent versus the Lang & Schwarz prior close of EUR 2.18. The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.